HK1212611A1 - 用於首次免疫对象的疫苗组合物 - Google Patents

用於首次免疫对象的疫苗组合物 Download PDF

Info

Publication number
HK1212611A1
HK1212611A1 HK16100580.8A HK16100580A HK1212611A1 HK 1212611 A1 HK1212611 A1 HK 1212611A1 HK 16100580 A HK16100580 A HK 16100580A HK 1212611 A1 HK1212611 A1 HK 1212611A1
Authority
HK
Hong Kong
Prior art keywords
composition
acid
vaccine
influenza
use according
Prior art date
Application number
HK16100580.8A
Other languages
English (en)
Chinese (zh)
Inventor
漢斯．阿爾維德松
汉斯．阿尔维德松
安娜-卡琳．馬爾泰斯
安娜-卡琳．马尔泰斯
Original Assignee
优若森疫苗公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 优若森疫苗公司 filed Critical 优若森疫苗公司
Publication of HK1212611A1 publication Critical patent/HK1212611A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
HK16100580.8A 2012-12-17 2013-12-17 用於首次免疫对象的疫苗组合物 HK1212611A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
EP12197522.1 2012-12-17
PCT/EP2013/077006 WO2014095943A1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects

Publications (1)

Publication Number Publication Date
HK1212611A1 true HK1212611A1 (zh) 2016-06-17

Family

ID=47358019

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16100580.8A HK1212611A1 (zh) 2012-12-17 2013-12-17 用於首次免疫对象的疫苗组合物
HK16101591.3A HK1213492A1 (zh) 2012-12-17 2013-12-17 用於免疫低下群体的疫苗组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16101591.3A HK1213492A1 (zh) 2012-12-17 2013-12-17 用於免疫低下群体的疫苗组合物

Country Status (12)

Country Link
US (2) US11065325B2 (https=)
EP (4) EP2742952A1 (https=)
JP (3) JP2016502997A (https=)
KR (3) KR20150132092A (https=)
CN (3) CN104884085A (https=)
AU (2) AU2013360890B2 (https=)
BR (2) BR112015014243A8 (https=)
CA (2) CA2895023A1 (https=)
HK (2) HK1212611A1 (https=)
MX (2) MX2015007688A (https=)
RU (2) RU2661408C2 (https=)
WO (2) WO2014095943A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101857839B1 (ko) * 2010-09-30 2018-05-14 유로씨네 백신즈 에이비 개선된 백신 조성물들
KR20230154072A (ko) 2014-09-26 2023-11-07 세퀴러스 유케이 리미티드 면역손상된 대상체의 백신 접종
EP3197487B1 (en) 2014-09-26 2022-08-03 Seqirus UK Limited Vaccination of immunocompromised subjects
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
EP4135520B1 (en) * 2020-04-16 2024-09-25 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
HUE069425T2 (hu) * 2020-04-16 2025-03-28 Bayer Ag Hatóanyag-kombinációk és azokat tartalmazó fungicid készítmények
HUE069397T2 (hu) * 2020-04-16 2025-03-28 Bayer Ag Hatóanyag-kombinációk és azokat tartalmazó fungicid készítmények
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
EP4463180A2 (en) * 2022-01-10 2024-11-20 The Children's Medical Center Corporation Methods and compositions relating to immunization of immune distinct patients

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
CA2439111A1 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
WO2004042000A2 (en) 2002-05-17 2004-05-21 Human Genome Sciences, Inc. 157 human secreted proteins
ES2352671T3 (es) 2002-11-26 2011-02-22 Eurocine Vaccines Ab Nuevo adyuvante a base de amina.
RU2390351C2 (ru) * 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
EP1885393A4 (en) 2005-05-18 2011-03-02 Childrens Hosp & Res Ct Oak METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIA INFECTIONS
CA2611721C (en) 2005-06-30 2014-04-22 Eisai Co., Ltd. Compounds for preparing immunological adjuvant
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
JP2011506290A (ja) * 2007-12-06 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザ組成物
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP2293814A4 (en) 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION AGENTS
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
KR101857839B1 (ko) 2010-09-30 2018-05-14 유로씨네 백신즈 에이비 개선된 백신 조성물들

Also Published As

Publication number Publication date
BR112015014174A2 (pt) 2017-07-11
AU2013360889C1 (en) 2017-06-08
EP3431101A1 (en) 2019-01-23
AU2013360890A1 (en) 2015-07-02
US20150306204A1 (en) 2015-10-29
MX2015007753A (es) 2016-01-08
EP2931308B1 (en) 2018-10-10
US20150306205A1 (en) 2015-10-29
JP2016502997A (ja) 2016-02-01
AU2013360889B2 (en) 2016-12-01
RU2661407C2 (ru) 2018-07-16
RU2015129028A (ru) 2017-01-23
JP2016502996A (ja) 2016-02-01
EP2742952A1 (en) 2014-06-18
US11065325B2 (en) 2021-07-20
BR112015014243A8 (pt) 2019-10-08
RU2015129077A (ru) 2017-01-23
CN112826929A (zh) 2021-05-25
BR112015014243A2 (pt) 2017-07-11
CA2895028A1 (en) 2014-06-26
WO2014095944A1 (en) 2014-06-26
HK1213492A1 (zh) 2016-07-08
JP2019112448A (ja) 2019-07-11
KR20150132093A (ko) 2015-11-25
EP2931307B1 (en) 2018-09-12
EP2931307A1 (en) 2015-10-21
EP2931308A1 (en) 2015-10-21
AU2013360890B2 (en) 2017-04-13
MX2015007688A (es) 2015-09-07
KR20150132092A (ko) 2015-11-25
WO2014095943A1 (en) 2014-06-26
CN104884085A (zh) 2015-09-02
CN104870010A (zh) 2015-08-26
AU2013360889A1 (en) 2015-07-02
RU2661408C2 (ru) 2018-07-16
CA2895023A1 (en) 2014-06-26
KR20210007042A (ko) 2021-01-19

Similar Documents

Publication Publication Date Title
HK1212611A1 (zh) 用於首次免疫对象的疫苗组合物
JP2019520090A (ja) 弱毒変異型ジカウイルスを含むワクチン組成物
JP2009209086A (ja) 粘膜投与型ワクチン
Gai et al. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV
US20240398930A1 (en) A vaccine for coronavirus and influenza virus, and method for preparation thereof
JP2023091085A (ja) 粘膜アジュバント
AU2007228736B2 (en) Intranasal influenza vaccine based on virosomes
TW201103980A (en) Viral vaccine and use thereof
US20080038294A1 (en) Intranasal or inhalational administration of virosomes
HK1128077B (en) Intranasal influenza vaccine based on virosomes
HK1128077A1 (en) Intranasal influenza vaccine based on virosomes
HK1170418A (en) Intranasal influenza vaccine based on virosomes